These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 23898119)
1. Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract. Ilhan-Mutlu A; Preusser M; Schoppmann SF; Asari R; Ba-Ssalamah A; Schwameis K; Pluschnig U; Birner P; Püspök A; Zacherl J; Hejna M Anticancer Res; 2013 Aug; 33(8):3455-9. PubMed ID: 23898119 [TBL] [Abstract][Full Text] [Related]
2. Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. Pluschnig U; Schoppmann SF; Preusser M; Datler P; Asari R; Ba-Ssalamah A; Schwameis K; Birner P; Zacherl J; Hejna M Anticancer Res; 2013 Mar; 33(3):1035-9. PubMed ID: 23482778 [TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521 [TBL] [Abstract][Full Text] [Related]
4. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer. Andersen M; Schønnemann KR; Yilmaz M; Jensen HA; Vestermark LW; Pfeiffer P Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725 [TBL] [Abstract][Full Text] [Related]
5. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer. Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751 [TBL] [Abstract][Full Text] [Related]
6. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Park SH; Park YH; Lee JN; Bang SM; Cho EK; Shin DB; Lee JH Cancer; 2006 Jan; 106(2):361-5. PubMed ID: 16342166 [TBL] [Abstract][Full Text] [Related]
8. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Van Cutsem E; Boni C; Tabernero J; Massuti B; Middleton G; Dane F; Reichardt P; Pimentel FL; Cohn A; Follana P; Clemens M; Zaniboni A; Moiseyenko V; Harrison M; Richards DA; Prenen H; Pernot S; Ecstein-Fraisse E; Hitier S; Rougier P Ann Oncol; 2015 Jan; 26(1):149-156. PubMed ID: 25416687 [TBL] [Abstract][Full Text] [Related]
9. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer. Amarantidis K; Xenidis N; Chelis L; Chamalidou E; Dimopoulos P; Michailidis P; Tentes A; Deftereos S; Karanikas M; Karayiannakis A; Kakolyris S Oncology; 2011; 80(5-6):359-65. PubMed ID: 21811088 [TBL] [Abstract][Full Text] [Related]
10. The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial. Ahmadzadeh A; Seyedian SS; Valizadeh A; Soleimani M; Nazari P; Hamidi H Asian Pac J Cancer Prev; 2020 Mar; 21(3):727-732. PubMed ID: 32212800 [TBL] [Abstract][Full Text] [Related]
11. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study. Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377 [TBL] [Abstract][Full Text] [Related]
12. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. Goel G; Jauhri M; Negi A; Aggarwal S Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537 [TBL] [Abstract][Full Text] [Related]
13. A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma. Petersen PC; Petersen LN; Vogelius I; Bjerregaard JK; Baeksgaard L Acta Oncol; 2021 Jul; 60(7):948-953. PubMed ID: 34086514 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey. Teker F; Yilmaz B; Kemal Y; Kut E; Yucel I Asian Pac J Cancer Prev; 2014; 15(16):6727-32. PubMed ID: 25169516 [TBL] [Abstract][Full Text] [Related]
15. Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer. Sirohi B; Barreto SG; Singh A; Batra S; Mittra A; Rastogia S; Ramadwar M; Shetty N; Goel M; Shrikhande SV J Cancer Res Ther; 2014; 10(4):866-70. PubMed ID: 25579520 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Wang Y; Zhuang RY; Yu YY; Yu S; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Liu FL; Zhao NQ; Liu TS Oncotarget; 2016 Nov; 7(46):76298-76307. PubMed ID: 27602586 [TBL] [Abstract][Full Text] [Related]
17. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer]. Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292 [TBL] [Abstract][Full Text] [Related]
18. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen. Sendur MA; Ozdemir N; Özatlı T; Yazıcı O; Aksoy S; Ekinci AS; Yazılıtaş D; Günaydın Y; Oksuzoglu B; Benekli M; Zengin N Med Oncol; 2014 Sep; 31(9):153. PubMed ID: 25099765 [TBL] [Abstract][Full Text] [Related]
19. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting. Kilickap S; Yalcin S; Ates O; Tekuzman G Hepatogastroenterology; 2011; 58(105):208-12. PubMed ID: 21510316 [TBL] [Abstract][Full Text] [Related]
20. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA; J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]